The First Purpose-Built Tool for Open Aortic Endograft Explant
The Hjärta Care XplantR is FDA-cleared, patented, and proven to reduce explant time from 15 minutes to under 90 seconds — protecting your patients and simplifying one of vascular surgery's most demanding procedures.
The Problem With Current Explant Techniques
Published literature confirms the frustration:
Dubois et al. (Journal of Vascular Surgery, Vol. 74) found the syringe resheathing technique was "rarely reported" and "often unsuccessful" in grafts that had been in place for some time.
Roughly 5% of EVAR grafts eventually require open surgical explant due to failure or infection. Yet until now, surgeons have been forced to rely on improvised workarounds — modified syringes, orthopedic wire cutters — that are bulky, inconsistent, and potentially traumatic to the aortic intima.
Arnaoutakis et al. (Journal of Vascular Surgery, Vol. 69) tried the syringe technique in two cases and found it "of limited help."
Extended suprarenal cross-clamp time — a direct consequence of difficult explants — has been linked to high morbidity and mortality in late EVAR conversion.
Introducing the XplantR
Designed in collaboration with Kellie R. Brown, MD, FACS, Professor of Vascular Surgery at the Medical College of Wisconsin, the XplantR was built around a single mandate: make explant simple, fast, and atraumatic.
Simple — No improvised tools. No cut syringes or bulky orthopedic wire cutters.
Atraumatic — A bullet-nose leading edge and tapered inner cylinder promote smooth advancement without damage to the aortic intima. Intimal inspection of all 120 De Novo study explants revealed no damage beyond the original suprarenal fixation puncture marks.
Fast — In the FDA De Novo approval study, 30 vascular surgeons averaged just 90 seconds per explant — including size selection, opening the package, inspection, and the explant itself.
Effective — Reduces suprarenal cross-clamp time, limiting the risk of end-organ failure and costly complications or readmission.
FDA Cleared for Commercial Distribution in the United States
The XlpantR has received FDA De Novo clearance and is available for ordering today.
U.S. Patent Nos. 11,351,047 and 12,396,871. International patents pending.
Animated Educational Video
Endo view of an explant in LifeLike BioTissue
Ready to Simplify Your Next Explant?
Whether you're a vascular surgeon evaluating the XplantR, a hospital supply chain manager, or Vascular Surgery Coordinator, we'd love to connect.
